Skip to main content
SpringerLink
Log in

Roxindole, a potential antidepressant I. Effect on the dopamine system

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Roxindole (EMD 49980, 5-hydroxy-3-[4-(4-phenyl-1,2,3,6-tetrahydropyridyl(1))-butyl(1)]-indole mesylate), a selective dopamine autoreceptor agonist and a potential antipsychotic drug, shows a clinical antidepressant efficacy. The present paper examined the neuropharmacological profile of roxindole in rats (male Wistar) and mice (male Albino Swiss) in respect of its influence on dopamine system. Used in low doses, roxindole decreased the locomotor activity, but in higher ones it did not induce a locomotor hyperactivity or stereotypy. It antagonized the amphetamine-induced hyperlocomotion, the amphetamine- or apomorphine-induced stereotypy, apomorphine climbing behaviour and reserpine-induced akinesia. The quinpirole-induced hyperlocomotion was inhibited by roxindole. When given alone, the drug in question, did not induce the catalepsy, but antagonized the catalepsy induced by haloperidol, spiperone and fluphenazine. The immobility time in the forced swimming test was reduced. Like typical antidepressants, roxindole given repeatedly (twice daily, 14 days) increased the hyperlocomotion induced by D-amphetamine.

The results described above indicate that roxindole may have an antidepressant and antiparkinsonian activity and should be devoid of extrapyramidal side-effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andén N-E, Golembiowska-Nikitin K, Thornström U (1982) Selective Stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn Schmiedebergs Arch Pharmacol 321: 100–104

    PubMed  Google Scholar 

  • Bartoszyk GD, Harting J, Minck KO (1996) Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J Pharmacol Exp Ther 276: 41–48

    PubMed  Google Scholar 

  • Benkert O, Gründer G, Wetzel H (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25: 254–260

    PubMed  Google Scholar 

  • Bravi D, Davis TL, Mouradian MM, Chase TN (1993) Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980. Mov Disord 8: 195–197

    PubMed  Google Scholar 

  • Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338: 191–195

    PubMed  Google Scholar 

  • Costall B, Naylor RJ (1972) Possible involvement of noradrenergic area of the amygdala with stereotyped behaviour. Life Sci 11 Part I: 1135–1146

    Google Scholar 

  • Delini-Stula A, Morpurgo C (1968) Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in rats. Int J Neuropharmacol 7: 391–397

    Google Scholar 

  • Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17: 289–309

    PubMed  Google Scholar 

  • Gründer G, Wetzel H, Hammes E, Benkert O (1993) Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology 111: 123–126

    PubMed  Google Scholar 

  • Harting J, Minck KO (1989) Pharmacological characterization of the dopamine autoreceptor agonist roxindole. Naunyn Schmiedebergs Arch Pharmacol 339: R 104

    Google Scholar 

  • Jaspers Ch, Benker G, Reinhardt W, Cissewski K, Lederbogen S, Schröder HG, Reinwein D (1992) A new non-ergot dopamine agonist (roxindol) for treatment of prolactinoma: first results. Acta Endocrinol 126 [Suppl 4]: 131

    Google Scholar 

  • Kasper S, Fuger J, Zinner HJ, Bäuml J, Möller HJ (1992) Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia — an open study. Eur Neuropsychopharmacol 2: 91–95

    PubMed  Google Scholar 

  • Klimek V, Maj J (1989) Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2 receptors. J Pharm Pharmacol 41: 555–558

    PubMed  Google Scholar 

  • Klimke A, Klieser E (1991) Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (roxindol). Pharmacopsychiatry 24: 107–112

    PubMed  Google Scholar 

  • Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99–113

    Google Scholar 

  • Maj J (1984) Central effects following repeated treatment with antidepressant drugs. Pol J Pharmacol Pharm 36: 87–89

    PubMed  Google Scholar 

  • Maj J, Rogóż Z, Skuza G, Sowińska H (1984) Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. J Pharm Pharmacol 36: 127–130

    PubMed  Google Scholar 

  • Maj J, Rogóż Z, Skuza G, Sowińska H (1985) The effects of repeated treatment with antidepressant drugs on the action of D-amphetamine and apomorphine in rats. In: Kelemen K, Magyar K, Vizi ES (eds) Neuropharmacology 1985. Akadémiai Kiadó, Budapest, pp 133–139

    Google Scholar 

  • Maj J, Rogóż Z, Skuza G, Sowińska H (1989) Antidepressants given repeatedly increase the behavioral effect of dopamine D-2 agonist. J Neural Transm [Gen Sect] 78: 1–8

    Google Scholar 

  • Maj J, Sarnek J, Klimek V, Rawlów A (1976) On the anticataleptic action of cyproheptadine. Pharmacol Biochem Behav 5: 201–205

    PubMed  Google Scholar 

  • Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379–391

    PubMed  Google Scholar 

  • Protais P, Costentin J, Schwartz JC (1976) Climbing behaviour induced by apomorphine in mice: a simple test for the study dopamine receptors in striatum. Psychopharmacology 50: 1–6

    PubMed  Google Scholar 

  • Pugsley TA, Christofferson CL, Corbin A, DeWald HA, Demattos S, Meltzer LT, Myers SL, Shih Y-H, Whetzel SZ, Wiley JN, Wise LD, Heffner TG (1992) Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist. J Pharmacol Exp Ther 263: 1147–1158

    PubMed  Google Scholar 

  • Serra G, Argiolas A, Klimek V, Fadda F, Gessa GL (1979) Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci 25: 415–424

    PubMed  Google Scholar 

  • Seyfried ChA, Bartoszyk GD (1994) Sensitivity of dopamine D2 receptors following long-term treatment with roxindole. Eur J Pharmacol 257: 67–72

    PubMed  Google Scholar 

  • Seyfried ChA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49 980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31–41

    PubMed  Google Scholar 

  • Spyraki Ch, Fibiger HC (1981) Behavioural evidence for supersensivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74: 195–206

    PubMed  Google Scholar 

  • Wiedemann K, Kellner M, Krieg J-C, Holsboer F (1992) Effects of the dopamine autoreceptor agonist roxindole in patients with depression. Clin Neuropharmacol 15 [Suppl 1B]: 175B

    Google Scholar 

  • Willner P (1983) Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res Rev 6: 237–246

    Google Scholar 

Download references

Author information

Author notes

  1. J. Maj

    Present address: Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

Authors and Affiliations

  1. Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

    K. Kotodziejczyk, Z. Rogóż & G. Skuza

Authors
  1. J. Maj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Kotodziejczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Rogóż
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Skuza
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maj, J., Kotodziejczyk, K., Rogóż, Z. et al. Roxindole, a potential antidepressant I. Effect on the dopamine system. J. Neural Transmission 103, 627–641 (1996). https://doi.org/10.1007/BF01273159

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01273159

Keywords

Search

Navigation